【摘要】：目的系統(tǒng)評價養(yǎng)血清腦顆粒治療中風后抑郁的療效及安全性,為臨床藥物治療提供循證依據(jù)。方法利用計算機檢索CNKI、中國生物醫(yī)學文獻數(shù)據(jù)庫(CBM)、萬方數(shù)據(jù)庫、維普期刊數(shù)據(jù)庫(VIP)、Pub Med、Cochrane Library等數(shù)據(jù)庫,搜集養(yǎng)血清腦顆粒治療中風后抑郁的隨機對照試驗,檢索時限為從建庫至2016年4月10日。指定2名評價員分別篩選文獻并對所納入研究進行方法學質(zhì)量評價,然后提取數(shù)據(jù)并利用RevMan5.3軟件完成Meta分析。結(jié)果最終10項隨機對照試驗納入本Meta分析,包含1035例患者。養(yǎng)血清腦顆粒聯(lián)合抗抑郁藥治療中風后抑郁≥28 d后,有效率、降低HAMD評分及NIHSS評分的療效均高于對照組(單獨應用抗抑郁藥)(P0.05);而不良反應發(fā)生率與對照組比較差異無統(tǒng)計學意義(P0.05)。養(yǎng)血清腦顆粒單獨用藥組的有效率、降低HAMD評分的療效及不良反應發(fā)生率與對照組比較差異均無統(tǒng)計學意義(均P0.05)。結(jié)論養(yǎng)血清腦顆粒能夠有效改善中風后抑郁癥狀,且治療效果與臨床上常用的抗抑郁藥基本相當,并具有良好的安全性。但還需要設計上更嚴謹?shù)亩嘀行摹⒋髽颖�、隨機對照試驗來進一步證實此結(jié)論。
[Abstract]:Objective to evaluate the efficacy and safety of Yangxuannao granule in the treatment of post-apoplectic depression, and to provide evidence-based evidence for clinical drug therapy. Methods CNKI, Chinese biomedical literature database (CBM), Wanfang database and Weipu periodical database (VIP), Pub Med,Cochrane Library database were searched by computer to collect the randomized controlled trial of Yangxuannao granule in the treatment of post-apoplectic depression. The time limit for retrieval is from the construction of the database to April 10, 2016. Two evaluators were appointed to sift through the literature and evaluate the methodological quality of the included research. Then the data were extracted and the Meta analysis was performed by RevMan5.3 software. Results Ten randomized controlled trials were included in this Meta analysis, including 1035 patients. The effective rate of Yangxuannao granule combined with antidepressant in the treatment of post-stroke depression 鈮，

本文編號：2265625